Royalty Pharma plc
RPRX
#720
Rank
$34.069 B
Marketcap
United States
Country
$59.17
Share price
0.57%
Change (1 day)
54.13%
Change (1 year)
Categories
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has…
Key Metrics
Trailing P/E
30.29
Forward P/E
10.29
EPS (TTM)
$1.90
Forward EPS
$5.59
Price / Book
3.71
EV / EBITDA
—
Beta
0.42
Dividend Yield
1.64%
Return on Equity
13.77%
Return on Assets
5.54%
Debt / Equity
90.32
Current Ratio
2.66
Gross Margin
115.00%
Operating Margin
100.30%
Net Profit Margin
33.86%
Free Cash Flow
$-980,302,528
Charts
Price history and financial performance over time.
Price & Market Cap
Jul 6 – Aug 4
+1.10%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$2.378B
Latest Net Income$770.947M
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare Royalty Pharma plc with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
RPRX
No recent news available. Set FINNHUB_API_KEY to enable news.
